Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

5.745 +0.055 (+0.97%)

Streaming Delayed Price Updated: 9:58 AM EDT, Jun 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	419,028
Open	5.690
Bid (Size)	5.740 (1,000)
Ask (Size)	5.750 (100)
Prev. Close	5.690
Today's Range	5.645 - 5.760
52wk Range	5.020 - 21.73
Shares Outstanding	98,983,261
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Wave Life Sciences to Present at Upcoming Investor Conferences

June 01, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.

Via The Motley Fool

Performance

YTD	-64.0%	-64.0%
1 Month	-23.1%	-23.1%
3 Month	-57.3%	-57.3%
6 Month	-17.8%	-17.8%
1 Year	-8.1%	-8.1%

More News

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

May 18, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference

May 13, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates ↗

April 28, 2026

Via Chartmill

Wave (WVE) Q1 2026 Earnings Call Transcript ↗

April 29, 2026

Via The Motley Fool

Wave (WVE) Q2 2025 Earnings Call Transcript ↗

April 28, 2026

Via The Motley Fool

Wave (WVE) Q1 2025 Earnings Call Transcript ↗

April 28, 2026

Via The Motley Fool

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

April 28, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector

April 22, 2026

Via Investor Brand Network

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

Via Investor Brand Network

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

From BioMedWire

Via GlobeNewswire

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

April 22, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

April 21, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Proposed Redomiciliation to the United States

April 15, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Is This Weight Loss Drug Stock a Buy on the Dip? ↗

April 01, 2026

Via The Motley Fool

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints ↗

March 26, 2026

Via The Motley Fool

Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗

March 26, 2026

Via Chartmill

Here are the top movers in Thursday's session. ↗

March 26, 2026

Via Chartmill

Thursday's session: gap up and gap down stocks ↗

March 26, 2026

Via Chartmill

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

Via MarketMinute

These stocks that are showing activity before the opening bell on Thursday. ↗

March 26, 2026

Via Chartmill

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

March 26, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

March 05, 2026

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences (WVE) Earnings Call Transcript ↗

February 27, 2026

Via The Motley Fool

Frequently Asked Questions

Is Wave Life Sciences Ltd. - Ordinary Shares publicly traded?

Yes, Wave Life Sciences Ltd. - Ordinary Shares is publicly traded.

What exchange does Wave Life Sciences Ltd. - Ordinary Shares trade on?

Wave Life Sciences Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares?

The ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares is WVE on the Nasdaq Stock Market

What is the current price of Wave Life Sciences Ltd. - Ordinary Shares?

The current price of Wave Life Sciences Ltd. - Ordinary Shares is 5.745

When was Wave Life Sciences Ltd. - Ordinary Shares last traded?

The last trade of Wave Life Sciences Ltd. - Ordinary Shares was at 06/03/26 09:58 AM ET

What is the market capitalization of Wave Life Sciences Ltd. - Ordinary Shares?

The market capitalization of Wave Life Sciences Ltd. - Ordinary Shares is 568.66M

How many shares of Wave Life Sciences Ltd. - Ordinary Shares are outstanding?

Wave Life Sciences Ltd. - Ordinary Shares has 569M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.